Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000;2(1):E3.
doi: 10.1208/ps020103.

Maturation and growth of renal function: dosing renally cleared drugs in children

W L Hayton  1
Affiliations

Maturation and growth of renal function: dosing renally cleared drugs in children

W L Hayton. AAPS PharmSci. 2000.

Abstract

A model was developed that characterized the maturation and growth of the renal function parameters (RFPs) glomerular filtration rate (GF), active tubular secretion (AS), and renal plasma flow (QR). Published RFP values were obtained from 63 healthy children between the ages of 2 days and 12 years. Maturation over time was assumed to be exponential from an immature (RFP(im)) to a mature (RFP(ma)) level; for growth, RFP(im) and RFP(ma) were assumed to follow the allometric equation: RFP (age, W) = aW(b)e(-kmat*age)+ cWb(1- e(-kmat*age)), where W is body weight, k(mat) is the maturation rate constant, b is the body weight exponent, and a and c are RFP(im) and RFP(ma) at unit W. The model-based equation was fitted to the age-W, RFP values by a nonlinear least-squares method. For GF, the maturation half-life was 7.9 months (90% maturation, 26 months), the body weight exponent was 0.662, and the ratio c/a (which reflected the magnitude of the maturation influence) was 3.1. For AS and QR, the maturation half-lives were about 3.8 months and the ratio c/a was about 1.8. For renally eliminated drugs, the model can be used to estimate dosing regimens that are based on the adult dosing regimen and the age and weight of the child.

PubMed Disclaimer

References

    1. Rowland M, Tozer T. Clinical Pharmacokinetics, Concepts and Applications. 3rd ed. Baltimore: Williams and Wilkins; 1995. pp. 83–105.
    1. Benet L, Oie S, Schwartz J. Appendix II: Design and optimization of dosage regimens; pharmacokinetic data. In: Hardman J, Limbird L, Molinoff P, Ruddon R, Gilman A, editors. Goodman And Gilmans The Pharmacological Basis Of Therapeutics. 9th ed. New York: McGraw-Hill; 1996. pp. 1707–1792.
    1. Crom WR. Pharmacokinetics in the child. Environ Health Perspect. 1994;102:111–117. - PMC - PubMed
    1. Rowland M, Tozer T. Clinical Pharmacokinetics, Concepts and Applications. 3rd ed. Baltimore: Williams and Wilkins; 1995. pp. 230–247.
    1. Lam YWF, Banerji S, Hatfield C, Talbert RL. Principles of drug administration in renal insufficiency. Clin Pharmacokinet. 1997;32:30–57. - PubMed

Substances